Alector Inc. has provided updates on its latest development portfolio and proprietary brain delivery platform in a recent corporate presentation. The company highlighted progress in its Phase 2 clinical trial for Alzheimer's disease, with interim analysis expected in the first half of 2026. Alector is advancing several brain-penetrant therapeutic candidates, including anti-amyloid beta antibodies, GCase enzyme replacement therapy, and small interfering RNA (siRNA) targeting tau, α-synuclein, and NLRP3. The presentation described the Alector Brain Carrier (ABC) platform, designed to facilitate efficient delivery of therapeutic molecules across the blood-brain barrier, with configurations adaptable for use with antibodies, enzymes, and nucleic acids. The company reported $291.1 million in cash, cash equivalents, and marketable securities as of November 6, 2025, providing a financial runway through 2027. You can access the full presentation through the link below.